Enlivex Ltd. ENLV
1.46 USD +0.04 (+2.82%)
At closeNov 3, 2026, 4:00 PM EST
1.43 -0.03 -2.05%
After hours · Nov 3, 4:00 PM ET
1.43 Day range 1.55
1.40 52-week range 434.40
- YTD
- -86.16%
- 1 year
- -90.73%
- Market cap
- 2.24M
- EPS (ttm)
- 8,072.17
- Shares out
- 21.99M
- P/E ratio
- 0.00
- Forward P/E
- -2.14
- YTD return
- -86.16%
- 1-year return
- -90.73%
- Volume
- 37.45K
- Avg volume
- 69.05K
- Open
- 1.43
- Previous close
- 1.42
- Day's range
- 1.43 – 1.55
- 52-week range
- 1.40 – 434.40
- Beta
- 1.10
- Analysts
- Strong Buy
- Price target
- 9.50 (+550.7%)
1D -0.01 (-0.70%)
Key statistics
- Enterprise value
- -1.30M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.98M
- Total cash
- 25.94M
- Total debt
- 835.00K
- Return on equity
- -61.17%
- Short % of float
- 0.49%
- 50-day average
- 1.27
- 200-day average
- 1.67
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 9.50 +550.7% upside
Now 1.46
- Target (low)
- 6.00
- Target (mean)
- 9.50
- Target (high)
- 13.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16.
Financials — quick view
ENLV Revenue — quarterly 0
ENLV Net income — quarterly 1.89B
ENLV EPS — quarterly 1,830.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 29, 2024 | Sep 1, 2024 | -0.16 | -0.12 | +0.04 | +25.00% |
| Aug 30, 2024 | Jun 1, 2024 | -0.22 | -0.16 | +0.06 | +27.27% |
| Jun 14, 2024 | Mar 1, 2024 | -0.25 | -0.22 | +0.03 | +12.00% |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.48 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.32 | -0.32 | 0.00 | 0.00% |
| Sep 1, 2023 | Jun 1, 2023 | -0.43 | -0.37 | +0.06 | +13.95% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 3, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 14, 2024 | D. Boral Capital | main | Buy | Buy |
| Sep 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 26, 2024 | EF Hutton | main | Buy | Buy |
| Sep 24, 2024 | EF Hutton | main | Buy | Buy |
About Enlivex Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- enlivex.com
News
Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response 
Enlivex Reports 135 Of 182 Planned Patients Randomized And Dosed In Phase 2b Knee Osteoarthritis Trial Of Allocetra; Topline Six-Month Data Expected By Mid-2027 
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis 
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal 
Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket 
Enlivex Reveals 1-For-16 Reverse Share Split To be Effective October 27, 2026 
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026 
12 Health Care Stocks Moving In Monday's After-Market Session 
Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027 
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Your note
Sign in to keep a note on ENLV — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 11.52% | 2,139,000 | 2.65M | Sep 29, 2024 |
| Morgan Stanley | 1.32% | 245,754 | 304.73K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.40% | 74,789 | 92.74K | Sep 29, 2024 |
| Sigma Investment Counselors Inc | 0.16% | 30,000 | 37.20K | Sep 29, 2024 |
| Xtx Topco Ltd | 0.12% | 22,659 | 28.10K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.08% | 13,935 | 17.28K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 10,420 | 12.92K | Oct 30, 2024 |